Cargando…

The dietary supplement Cyplexinol(®) alleviates joint pain in men and women

BACKGROUND AND AIM: Joint pain afflicts millions of adults worldwide. The effect of a bone morphogenetic protein complex on joint pain is assessed in this study. METHODS: We compared the impact of a dietary supplement protein complex (Cyplexinol(®)) and placebo in 18 men and women (aged 43 ± 10 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Pence, Jacquelyn, Stockton, Michelle, Bloomer, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Whioce Publishing Pte. Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339409/
https://www.ncbi.nlm.nih.gov/pubmed/37457546
_version_ 1785071839046795264
author Pence, Jacquelyn
Stockton, Michelle
Bloomer, Richard J.
author_facet Pence, Jacquelyn
Stockton, Michelle
Bloomer, Richard J.
author_sort Pence, Jacquelyn
collection PubMed
description BACKGROUND AND AIM: Joint pain afflicts millions of adults worldwide. The effect of a bone morphogenetic protein complex on joint pain is assessed in this study. METHODS: We compared the impact of a dietary supplement protein complex (Cyplexinol(®)) and placebo in 18 men and women (aged 43 ± 10 years) with self-reported joint pain. Subjects were randomly assigned to each condition, consumed twice daily for 14 days (900 mg/day). Subjects completed questionnaires (e.g., Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subjective pain using a visual analog scale [VAS]) at the start and end of each treatment phase. Blood samples were analyzed for bone morphogenic protein (BMP), alkaline phosphatase, and cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-10, IL-1β, and TGF-β). Blood was also collected on days 1 and 15 to determine the acute impact of treatment on these measures. RESULTS: Pain and discomfort scores improved (P ≤ 0.05) for subjects following use of Cyplexinol(®) but not placebo. Improvements were noted for WOMAC pain (P = 0.05), stiffness (P = 0.039), and total pain (P = 0.026), as well as VAS pain (P = 0.015), recreational activity interference (P = 0.023), mood interference (P = 0.012), and total pain (P = 0.024). A trend was noted for WOMAC physical function (P = 0.052). An approximate 50% increase in BMP5 was noted following Cyplexinol(®) (P = 0.01), with a similar increase noted for placebo (P = 0.022). A near doubling in TGF-β (P = 0.001) was noted for Cyplexinol(®). No other changes of significance were noted across time, nor were any differences noted in cytokines following acute intake of the conditions (P > 0.05). CONCLUSIONS: Cyplexinol(®) can alleviate joint pain in middle-aged men and women, while elevating BMP5 and TGF-β. Cyplexinol(®) does not influence cytokines, at least within a short 2-week supplementation period or within the 2-h post-ingestion period. RELEVANCE FOR PATIENTS: Individuals suffering with joint pain in the knee and/or hip may benefit from daily use of Cyplexinol(®), as we observed decreased pain and stiffness following treatment.
format Online
Article
Text
id pubmed-10339409
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Whioce Publishing Pte. Ltd.
record_format MEDLINE/PubMed
spelling pubmed-103394092023-07-14 The dietary supplement Cyplexinol(®) alleviates joint pain in men and women Pence, Jacquelyn Stockton, Michelle Bloomer, Richard J. J Clin Transl Res Original Article BACKGROUND AND AIM: Joint pain afflicts millions of adults worldwide. The effect of a bone morphogenetic protein complex on joint pain is assessed in this study. METHODS: We compared the impact of a dietary supplement protein complex (Cyplexinol(®)) and placebo in 18 men and women (aged 43 ± 10 years) with self-reported joint pain. Subjects were randomly assigned to each condition, consumed twice daily for 14 days (900 mg/day). Subjects completed questionnaires (e.g., Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subjective pain using a visual analog scale [VAS]) at the start and end of each treatment phase. Blood samples were analyzed for bone morphogenic protein (BMP), alkaline phosphatase, and cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-10, IL-1β, and TGF-β). Blood was also collected on days 1 and 15 to determine the acute impact of treatment on these measures. RESULTS: Pain and discomfort scores improved (P ≤ 0.05) for subjects following use of Cyplexinol(®) but not placebo. Improvements were noted for WOMAC pain (P = 0.05), stiffness (P = 0.039), and total pain (P = 0.026), as well as VAS pain (P = 0.015), recreational activity interference (P = 0.023), mood interference (P = 0.012), and total pain (P = 0.024). A trend was noted for WOMAC physical function (P = 0.052). An approximate 50% increase in BMP5 was noted following Cyplexinol(®) (P = 0.01), with a similar increase noted for placebo (P = 0.022). A near doubling in TGF-β (P = 0.001) was noted for Cyplexinol(®). No other changes of significance were noted across time, nor were any differences noted in cytokines following acute intake of the conditions (P > 0.05). CONCLUSIONS: Cyplexinol(®) can alleviate joint pain in middle-aged men and women, while elevating BMP5 and TGF-β. Cyplexinol(®) does not influence cytokines, at least within a short 2-week supplementation period or within the 2-h post-ingestion period. RELEVANCE FOR PATIENTS: Individuals suffering with joint pain in the knee and/or hip may benefit from daily use of Cyplexinol(®), as we observed decreased pain and stiffness following treatment. Whioce Publishing Pte. Ltd. 2023-04-26 /pmc/articles/PMC10339409/ /pubmed/37457546 Text en Copyright: © 2023 Author(s). https://creativecommons.org/licenses/by-nc/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution-Noncommercial License, permitting all noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Pence, Jacquelyn
Stockton, Michelle
Bloomer, Richard J.
The dietary supplement Cyplexinol(®) alleviates joint pain in men and women
title The dietary supplement Cyplexinol(®) alleviates joint pain in men and women
title_full The dietary supplement Cyplexinol(®) alleviates joint pain in men and women
title_fullStr The dietary supplement Cyplexinol(®) alleviates joint pain in men and women
title_full_unstemmed The dietary supplement Cyplexinol(®) alleviates joint pain in men and women
title_short The dietary supplement Cyplexinol(®) alleviates joint pain in men and women
title_sort dietary supplement cyplexinol(®) alleviates joint pain in men and women
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339409/
https://www.ncbi.nlm.nih.gov/pubmed/37457546
work_keys_str_mv AT pencejacquelyn thedietarysupplementcyplexinolalleviatesjointpaininmenandwomen
AT stocktonmichelle thedietarysupplementcyplexinolalleviatesjointpaininmenandwomen
AT bloomerrichardj thedietarysupplementcyplexinolalleviatesjointpaininmenandwomen
AT pencejacquelyn dietarysupplementcyplexinolalleviatesjointpaininmenandwomen
AT stocktonmichelle dietarysupplementcyplexinolalleviatesjointpaininmenandwomen
AT bloomerrichardj dietarysupplementcyplexinolalleviatesjointpaininmenandwomen